Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuzhu Diao

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
BMC Cancer|July 28, 2022
Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitorsZhenzhen Liu, Yuzhu Diao, Xiaoling Li
Medicine|July 12, 2024
Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case reportJielin Li, Meizi Jin, Yuzhu Diao, et al.
International Journal of Environmental Research and Public Health|March 3, 2018
Grey Language Hesitant Fuzzy Group Decision Making Method Based on Kernel and Grey ScaleQingsheng Li, Yuzhu Diao, Zaiwu Gong, et al.
Journal of Thoracic Disease|May 25, 2026
Association of body mass index and serum markers with immune-related adverse events in lung cancer patients receiving immune checkpoint inhibitorsZhenzhen Liu, Yuzhu Diao, Shuchen Chen, et al.
Cancer Medicine|September 26, 2022
Identification of nine mutant genes and establishment of three prediction models of organ tropism metastases of non-small cell lung cancerShuchen Chen, Wanyi Huang, Zhenzhen Liu, et al.
Cancer Medicine|May 8, 2022
Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategiesShuchen Chen, Honglin Zhu, Meizi Jin, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
BMC Cancer|July 28, 2022
Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitorsZhenzhen Liu, Yuzhu Diao, Xiaoling Li
Medicine|July 12, 2024
Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case reportJielin Li, Meizi Jin, Yuzhu Diao, et al.
International Journal of Environmental Research and Public Health|March 3, 2018
Grey Language Hesitant Fuzzy Group Decision Making Method Based on Kernel and Grey ScaleQingsheng Li, Yuzhu Diao, Zaiwu Gong, et al.
Journal of Thoracic Disease|May 25, 2026
Association of body mass index and serum markers with immune-related adverse events in lung cancer patients receiving immune checkpoint inhibitorsZhenzhen Liu, Yuzhu Diao, Shuchen Chen, et al.
Cancer Medicine|September 26, 2022
Identification of nine mutant genes and establishment of three prediction models of organ tropism metastases of non-small cell lung cancerShuchen Chen, Wanyi Huang, Zhenzhen Liu, et al.
Cancer Medicine|May 8, 2022
Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategiesShuchen Chen, Honglin Zhu, Meizi Jin, et al.
Pageof 1